Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of large B-cell lymphoma that didn't respond to or came back within 12 months of finishing your first treatment.
- Your first treatment included a CD20-targeting antibody and an anthracycline chemotherapy.
- You have at least one measurable tumor on a scan.
- You have not had any other cancer treatment (except steroids or local radiation) since your first therapy.
- Your organs (kidneys, liver, heart, lungs) are working well enough, and your blood counts are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This early-stage trial tests an automated version of axicabtagene ciloleucel (a CAR-T cell therapy) for large B-cell lymphoma that has come back or stopped responding to initial chemotherapy. CAR-T therapy uses your own immune cells, modified in a lab to fight cancer cells.
This trial tests whether a second infusion of a CAR-T cell therapy called Axi-cel, given early based on a blood test (ctDNA), can help people with relapsed or hard-to-treat large B-cell lymphoma. If you had a partial response or your ctDNA stayed positive after the first dose, you may be eligible.
This trial tests whether a type of immunotherapy called axicabtagene ciloleucel (a CAR T-cell therapy) can improve outcomes when given right after initial treatment for high-risk large B-cell lymphoma. It is for people who have not yet started treatment.
Hear when a new Relapsed or Refractory Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.